0QKQ
vs
S
Swiss Market Index
0QKQ
Over the past 12 months, 0QKQ has underperformed Swiss Market Index, delivering a return of -85% compared to the Swiss Market Index's +11% growth.
Stocks Performance
0QKQ vs Swiss Market Index
Performance Gap
0QKQ vs Swiss Market Index
Performance By Year
0QKQ vs Swiss Market Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Relief Therapeutics Holding SA
Glance View
RELIEF THERAPEUTICS Holding AG is a clinical stage biotechnology company. The company is headquartered in Geneve, Geneve and currently employs 55 full-time employees. The company went IPO on 2011-09-19. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. The company specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The firm is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
